（文章来源：证券日报） 证券日报网讯 10月13日晚间，罗欣药业发布公告称，董事会同意聘任姜英女士为公司董事会秘书。 ...

证券日报网讯 10月13日晚间，罗欣药业发布公告称，同意提名韩风生先生为公司第五届非独立董事候 选人。 （文章来源：证券日报） ...

Core Viewpoint - Luo Xin Pharmaceutical (002793) announced the appointment of Jiang Ying as the new company secretary to enhance corporate governance and ensure proper operations [1] Group 1: Appointment Details - Jiang Ying was nominated by the chairman and approved by the board of directors, with her term lasting until the end of the fifth board of directors [1] - Jiang Ying holds dual bachelor's degrees in Science and Economics from Peking University, as well as a master's degree in Management from Peking University and a master's degree in Finance from the University of Hong Kong [1] Group 2: Professional Background - Jiang Ying has previously worked as an analyst at Guotai Junan Securities Asset Management, and at Everbright Pramerica Fund [1] - She has also served as an analyst, assistant fund manager, and fund manager at Guotai Fund [1]

Group 1 - The company announced the resignation of Mr. Han Fengsheng as the Secretary of the Board due to job relocation, while he will continue to serve as a director in the company's subsidiary, Shandong Luoxin Pharmaceutical Group Co., Ltd [1] - Ms. Jiang Ying has been appointed as the new Secretary of the Board following the nomination by the Chairman and approval by the Board of Directors [1] - As of the report date, the company's market capitalization is 5.3 billion yuan [1] Group 2 - For the first half of 2025, the company's revenue composition is as follows: pharmaceutical manufacturing accounts for 88.11%, pharmaceutical commerce for 10.1%, and other businesses for 1.79% [1]

一、董事会秘书职务调整情况 证券代码：002793 证券简称：罗欣药业 公告编号：2025-090 罗欣药业集团股份有限公司 关于聘任董事会秘书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 《公司章程》等相关规定要求。姜英女士目前尚未取得深圳证券交易所颁发的《董 事会秘书培训证明》，承诺将尽快完成培训，取得董事会秘书培训证明。 姜英女士联系方式如下： 通讯地址：上海市浦东新区东育路 255 弄 4 号前滩世贸中心一期 A 栋 7 层 特此公告。 罗欣药业集团股份有限公司董事会 罗欣药业集团股份有限公司（以下简称"公司"）近日收到董事会秘书韩风 生先生递交的书面辞职报告。因工作调动原因，韩风生先生申请辞去公司董事会 秘书职务，辞职后，继续在公司控股子公司山东罗欣药业集团股份有限公司担任 董事。截至本公告披露日，韩风生先生未直接持有公司股份，其通过认购公司 2024 年员工持股计划间接持有公司股份 100 万股。韩风生先生间接持有的股份 仍将严格按照《上市公司股东减持股份管理暂行办法》《深圳证券交易所上市公 司自律监管指引第 18 号——股东及董事、高级 ...

证券代码：002793 证券简称：罗欣药业 公告编号：2025-092 罗欣药业集团股份有限公司 关于增选公司非独立董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》《深圳证券交易所股票上市规则》等法律法 规、规范性文件及《公司章程》的有关规定，为完善公司治理结构，进一步提高 决策效率，经公司提名委员会资格审查，董事会提名韩风生先生为公司第五届董 事会非独立董事候选人，任期自股东大会审议通过之日起至公司第五届董事会届 满之日止，韩风生先生的简历参见附件。 本次增选的非独立董事当选后，董事会中兼任公司高级管理人员及由职工代 表担任的董事人数总计不超过公司董事总数的二分之一。 特此公告。 罗欣药业集团股份有限公司董事会 2025 年 10 月 13 日 1 附件：个人简历 韩风生先生，1975 年出生，中国国籍，无境外永久居留权，本科学历。1996 年 8 月至 2001 年 11 月任职于罗欣医药集团有限公司。2001 年 11 月至今任职于 山东罗欣药业集团股份有限公司（以下简称"山东罗欣"），现任山东罗欣董事 及公司控股 ...

2025 年 10 月 13 日，罗欣药业集团股份有限公司（以下简称"公司"）第 五届董事会第三十一次会议在山东省临沂高新技术产业开发区罗七路管理中心 三楼会议室和上海市浦东新区前滩世贸中心会议室以现场表决和通讯表决相结 合的方式召开。会议通知已于 2025 年 10 月 10 日以电话、专人送达、电子邮件 等方式发出。本次会议应出席董事 5 名，实际出席董事 5 名，公司监事、董事会 秘书、拟受聘人员列席了会议。公司董事长刘振腾先生主持了本次会议。会议的 召集、召开符合《中华人民共和国公司法》等法律法规、规范性文件和《罗欣药 业集团股份有限公司章程》的规定，合法有效。 二、董事会会议审议情况 证券代码：002793 股票简称：罗欣药业 公告编号：2025-091 罗欣药业集团股份有限公司 第五届董事会第三十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 三、备查文件 （一）审议通过《关于聘任董事会秘书的议案》 韩风生先生因工作调动原因申请辞去公司董事会秘书的职务，辞职后，继续 在公司控股子公司山东罗欣药业集团股份有限 ...

Core Viewpoint - 罗欣药业 plans to raise up to 842 million yuan through a private placement of shares to fund innovative drug research, raw material drug expansion, and working capital supplementation, without changing its control [1] Fundraising and Project Allocation - The company intends to issue no more than 326,276,545 A-shares, raising a total of up to 842 million yuan for various projects [1] - Among the fundraising projects, 226 million yuan is allocated for innovative drug research, with 207 million yuan sourced from the raised funds [2] - The innovative drug research includes clinical studies for LX22001 and Tegoprazan, aimed at expanding treatment indications and enhancing market competitiveness [2] Raw Material Drug Expansion and Technological Upgrades - The raw material drug expansion and freeze-drying workshop technological upgrade project has a total investment of 476 million yuan, with 383 million yuan planned to be funded from the raised capital [3] - This project aims to upgrade production standards and respond to regulatory trends, while also supporting the company's international development strategy [3] Financial Performance and Historical Context - Since its A-share listing in 2020, the company has faced significant financial instability, with cumulative losses exceeding 2.8 billion yuan over the past three years [4] - Revenue figures from 2020 to 2024 show a decline from 60.96 billion yuan to 26.47 billion yuan, with a notable drop of 44.62% in 2022 [5] - The company reported a net profit of 3.21 billion yuan in 2020, which fell to a loss of 12.25 billion yuan in 2022, reflecting a 401.63% decline [5] Market Position and Product Development - The company has been actively developing innovative drugs, with Tegoprazan being a significant contributor to revenue growth, particularly in the digestive system category [6] - Sales of Tegoprazan increased by 163.63% and 43.11% in 2023 and 2024, respectively, with a nearly 140% increase in the first half of 2025 compared to the previous year [6] Research and Development Expenditure - R&D expenses have been declining from 361 million yuan in 2020 to 87 million yuan in 2024, while sales expenses have remained significantly higher [7] - The company reported a revenue of 1.077 billion yuan in the first half of 2025, a 14.45% decrease year-on-year, but a net profit of 17.69 million yuan, marking a 119.95% increase [7] Management Changes - The company has experienced frequent changes in its management team, with several key resignations occurring in 2024 and 2025 [7]

Group 1 - Pingzhi Information has been selected as the eighth candidate for the "2025 China Unicom General Server Centralized Procurement Project" with a bid amount of approximately 451 million yuan [1] - The project involves the procurement of general servers primarily for cloud computing infrastructure [1] - Pingzhi Information was established in November 2002 and focuses on communication equipment, computing power, and operator equity products [1] Group 2 - Betta Pharmaceuticals has submitted an application for the issuance of H shares and listing on the Hong Kong Stock Exchange [2] - Betta Pharmaceuticals was founded in January 2003 and specializes in the production and sales of innovative drugs [2] Group 3 - Guangli Micro plans to sign an agreement with Zhejiang University to establish a joint research center for silicon photonics technology and measurement equipment [3] - The company will invest no less than 15 million yuan over three years for the center's development [3] - Guangli Micro was founded in August 2003 and provides a range of services including integrated circuit manufacturing and design [3] Group 4 - Shanhe Pharmaceutical's controlling shareholder and actual controller has changed due to the passing of Yin Zhenglong, with his wife and daughter inheriting shares [4] - After the change, Wu Changhong holds 20.172% of the total shares, while Yin Zhiya holds 6.724% [4] - Shanhe Pharmaceutical was established in April 2001 and focuses on the research, production, and sales of pharmaceutical excipients [5] Group 5 - Hengwei Technology plans to acquire 75% of Shanghai Shuhang Information Technology Co., Ltd. through a combination of share issuance and cash payment [6] - The acquisition will make Shuhang Technology a subsidiary of Hengwei Technology [6] - Hengwei Technology was founded in March 2003 and specializes in intelligent system solutions [7] Group 6 - Shougang Co. intends to repurchase its A-shares for an amount between 260 million yuan and 520 million yuan [8] - The repurchase will be used for implementing an equity incentive plan [8] - Shougang Co. was established in October 1999 and focuses on the production and sales of steel products [9] Group 7 - Pulit plans to build a 6GWh sodium-ion battery production base in Sichuan with a total investment of approximately 800 million yuan [10] - The project will be constructed in two phases, with the first phase having a capacity of 2GWh [10] - Pulit was founded in October 1999 and specializes in high polymer new materials and battery production [10] Group 8 - Saisir has proposed a cash dividend of 3.1 yuan per 10 shares for its A-share shareholders [10] - Saisir was established in May 2007 and focuses on the research, manufacturing, and sales of new energy vehicles [10] Group 9 - Guangyang Co. plans to establish a wholly-owned subsidiary for the development of precision components for robots [11] - The investment is part of a project to produce high-end components for new energy vehicles and robots [11] - Guangyang Co. was founded in April 1995 and specializes in precision components for various vehicles and equipment [11] Group 10 - Conch New Materials intends to acquire a 51% stake in North China Industrial Plastics Co., Ltd. for approximately 95.27 million yuan [12] - The acquisition will make North China Plastics a subsidiary of Conch New Materials [12] - Conch New Materials was established in October 1996 and focuses on the production and sales of plastic profiles and aluminum profiles [12] Group 11 - Daikin Heavy Industries has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [13] - The company specializes in the production and sales of offshore wind power equipment [13] - Daikin Heavy Industries was founded in September 2003 [13] Group 12 - Tengya Precision plans to invest up to 8 million USD to establish a subsidiary in Vietnam for the production of garden robots and electric tools [14] - The project will involve leasing a factory in Dong Nai Province [14] - Tengya Precision was established in August 2000 and focuses on power tools and building hardware [15] Group 13 - Luoxin Pharmaceutical plans to raise up to 207 million yuan through a private placement for innovative drug research and development [16] - The funds will primarily support clinical research for specific innovative drugs [16] - Luoxin Pharmaceutical was founded in May 1998 and specializes in pharmaceutical product development [17] Group 14 - *ST Guohua's subsidiary has become the first candidate for a project with a bid of 236 million yuan [18] - The project involves a 90-day construction period [18] - *ST Guohua was established in May 1986 and focuses on mobile network security [19] Group 15 - Su Chen Technology plans to acquire 60% of Likong Technology for a total price of 192 million yuan [20] - The acquisition will make Likong Technology a secondary subsidiary of Su Chen Technology [20] - Su Chen Technology was founded in February 2006 and specializes in CAE software development [21] Group 16 - Qingmu Technology's major shareholder plans to reduce their stake by up to 276,000 shares [22] - The reduction is due to the shareholder's financial needs [22] - Qingmu Technology was established in August 2009 and provides comprehensive e-commerce operation services [23] Group 17 - Tongda Sea plans to acquire 40% of Jiangsu Sufuda Data Technology Co., Ltd. for 25.64 million yuan [24] - The acquisition will result in Tongda Sea holding 100% of Sufuda [24] - Tongda Sea was founded in March 1995 and provides information technology services for electronic government affairs [24] Group 18 - Rongsheng Development has signed a memorandum of cooperation to promote the development of the seaplane industry [25] - The cooperation will focus on infrastructure construction and talent training [25] - Rongsheng Development was established in December 1996 and specializes in real estate development [26] Group 19 - Jinma Amusement plans to repurchase 16.52% of its subsidiary for 60 million yuan [28] - The repurchase will convert the subsidiary into a wholly-owned entity [28] - Jinma Amusement was founded in November 2007 and focuses on amusement facilities and projects [28] Group 20 - Huilv Ecology plans to acquire 49% of Junheng Technology for 1.127 billion yuan [29] - The acquisition will make Junheng Technology a wholly-owned subsidiary [29] - Huilv Ecology was established in January 1990 and specializes in optical communication products and landscape engineering [30]

中国经济网北京9月30日讯 罗欣药业(002793.SZ)昨日晚间披露2025年度向特定对象发行A股股票预案。 罗欣药业本次向特定对象发行股票预计募集资金总额不超过84,240万元（含本数），发行股票数量按照募集资金总额除以发行价格确定，计划用于创新 药研发项目、原料药改扩建及冻干车间技改项目、补充流动资金。 | | | | 早征: 月九 | | --- | --- | --- | --- | | 序号 | 项目名称 | 项目投资总额 | 拟使用募集资金金额 | | | 创新药研发项目 | 22,603.00 | 20,708.00 | | 2 | 原料药改扩建及冻干车间技改项目 | 47,567.00 | 38,262.00 | | 3 | 补充流动资金 | 25,270.00 | 25,270.00 | | | 合计 | 95,440.00 | 84,240.00 | 本次向特定对象发行股票相关事项已经公司于2025年9月29日召开的第五届董事会第三十次会议、第五届监事会第二十五次会议审议通过。根据《公司 法》《证券法》及《注册管理办法》等相关法律、法规和规范性文件的规定，本次发行尚需取得公司股东大会审议 ...